{"id":"iglarlixi","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin glargine provides long-acting basal insulin replacement to control fasting and between-meal blood glucose levels. Lixisenatide is a GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, slows gastric emptying, and reduces glucagon secretion, thereby improving postprandial glucose control. The combination addresses both fasting and postprandial hyperglycemia in a single injection.","oneSentence":"iGlarLixi is a fixed-ratio combination of insulin glargine and lixisenatide that lowers blood glucose by providing basal insulin coverage and enhancing insulin secretion via GLP-1 receptor activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:59.966Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06671587","phase":"PHASE4","title":"iGlarLixi CGM Study in Chinese T2D Individuals After OADs","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Type 2 Diabetes (T2D)","enrollment":678},{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT06716424","phase":"PHASE4","title":"A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-01-06","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT07307235","phase":"PHASE4","title":"Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-15","conditions":"Type 2 Diabetes","enrollment":1316},{"nctId":"NCT07274644","phase":"PHASE4","title":"Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease","status":"ENROLLING_BY_INVITATION","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2025-03-29","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease, Diabetes Mellitus Type 2","enrollment":36},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT05114590","phase":"PHASE4","title":"Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-01-27","conditions":"Type 2 Diabetes Mellitus","enrollment":124},{"nctId":"NCT05591391","phase":"NA","title":"The Efficacy of Mallya in Type 2 Diabetes Transiting From Oral Antidiabetic Drugs to iGlarLixi","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2022-09-28","conditions":"Mallya","enrollment":40},{"nctId":"NCT04893148","phase":"PHASE4","title":"Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Chungbuk National University Hospital","startDate":"2020-05-26","conditions":"Type 2 Diabetes Mellitus, Glucose, High Blood","enrollment":40},{"nctId":"NCT03798080","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-02-19","conditions":"Type 2 Diabetes Mellitus","enrollment":426},{"nctId":"NCT03798054","phase":"PHASE3","title":"Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-02-15","conditions":"Type 2 Diabetes Mellitus","enrollment":878},{"nctId":"NCT03529123","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-06-19","conditions":"Type 2 Diabetes Mellitus","enrollment":247},{"nctId":"NCT03767543","phase":"PHASE3","title":"Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-11","conditions":"Type 2 Diabetes Mellitus","enrollment":265},{"nctId":"NCT03434119","phase":"PHASE3","title":"Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-02-20","conditions":"Type 2 Diabetes Mellitus","enrollment":241},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT04945070","phase":"PHASE4","title":"INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi","status":"UNKNOWN","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2021-07","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":96},{"nctId":"NCT03819790","phase":"PHASE4","title":"The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2018-10-02","conditions":"Diabetes Mellitus, Type 2","enrollment":119},{"nctId":"NCT03130426","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2017-06-27","conditions":"Type 2 Diabetes Mellitus","enrollment":161},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT03881995","phase":"PHASE4","title":"Effects of Insulin Glargine and Lixisenatide on the Brain","status":"TERMINATED","sponsor":"University Hospital Tuebingen","startDate":"2019-03-18","conditions":"Diabetes Mellitus, Type 2","enrollment":1},{"nctId":"NCT03959865","phase":"","title":"GLP-1 REceptor Agonists and Real World EvIdeNce","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2018-12-19","conditions":"Type 2 Diabetes","enrollment":6000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":161,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["glargine insulin / lixisenatide"],"phase":"marketed","status":"active","brandName":"iGlarLixi","genericName":"iGlarLixi","companyName":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","companyId":"the-affiliated-nanjing-drum-tower-hospital-of-nanjing-university-medical-school","modality":"Small molecule","firstApprovalDate":"","aiSummary":"iGlarLixi is a fixed-ratio combination of insulin glargine and lixisenatide that lowers blood glucose by providing basal insulin coverage and enhancing insulin secretion via GLP-1 receptor activation. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}